113 related articles for article (PubMed ID: 20850023)
1. [Budesonide/formoterol in the treatment of COPD].
Peces-Barba Romero G; Villar Alvarez F
Arch Bronconeumol; 2010; 46 Suppl 4():22-7. PubMed ID: 20850023
[TBL] [Abstract][Full Text] [Related]
2. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
3. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
4. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
6. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
[TBL] [Abstract][Full Text] [Related]
7. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
10. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
[TBL] [Abstract][Full Text] [Related]
11. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
12. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease.
Cazzola M
Pulm Pharmacol Ther; 2006; 19(2):79-89. PubMed ID: 15964228
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
Kerwin EM; Oppenheimer JJ; LaForce C; Parasuraman B; Miller CJ; O'Dowd L; Goldman M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation.
Santus P; Centanni S; Verga M; Di Marco F; Matera MG; Cazzola M
Respir Med; 2006 Jul; 100(7):1277-81. PubMed ID: 16337781
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
16. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study.
van Schayck OC; Haughney J; Aubier M; Selroos O; Ekström T; Ostinelli J; Buhl R
Respir Med; 2012 Feb; 106(2):189-96. PubMed ID: 22119455
[TBL] [Abstract][Full Text] [Related]
17. Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control.
Ceylan E; Gencer M; Aksoy S
Respiration; 2004; 71(6):594-601. PubMed ID: 15627870
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
[TBL] [Abstract][Full Text] [Related]
20. Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA; Perry CM; Keating GM
Drugs; 2004; 64(4):431-41; discussion 433-4. PubMed ID: 14969576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
